Oscar Health, Inc. (NYSE: OSCR) saw its stock surge 6.28% in pre-market trading on Thursday, following the release of its third-quarter 2025 financial results. The health insurance technology company reported better-than-expected earnings per share, despite missing revenue estimates, and reaffirmed its full-year 2025 guidance.

Oscar Health reported a quarterly loss of $0.53 per share, beating analyst consensus estimates of a $0.61 loss by 13.26%. While this represents a wider loss compared to the $0.22 per share loss in the same quarter last year, investors appeared to focus on the company's ability to outperform expectations. Revenue for the quarter came in at $2.986 billion, slightly below the analyst estimate of $3.082 billion, but still showing a significant 23.24% increase from the $2.423 billion reported in the same period last year.

The company's decision to reaffirm its full-year 2025 outlook seems to have further boosted investor confidence, despite the mixed results. Oscar Health's adjusted EBITDA for Q3 was reported at -$101.453 million, slightly worse than the -$96.1 million estimated by analysts. However, the market's positive reaction suggests that investors are focusing on the company's ability to navigate challenges and maintain its forward guidance in a competitive health insurance landscape.